Senseonics Holdings, Inc. Common Stock (NASDAQ:SENS) Receives Consensus Rating of “Moderate Buy” from Analysts

Shares of Senseonics Holdings, Inc. Common Stock (NASDAQ:SENS) have received an average recommendation of “Moderate Buy” from the six research firms that are presently covering the company, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and four have issued a buy recommendation on the company. The average 12 month target price among brokers that have updated their coverage on the stock in the last year is $17.20.

Several equities analysts have weighed in on SENS shares. HC Wainwright lowered their price objective on shares of Senseonics Holdings, Inc. Common Stock from $18.50 to $14.00 and set a “buy” rating on the stock in a research report on Tuesday, May 12th. Wall Street Zen upgraded Senseonics Holdings, Inc. Common Stock from a “strong sell” rating to a “sell” rating in a report on Saturday, August 8th. Stifel Nicolaus lowered their target price on shares of Senseonics Holdings, Inc. Common Stock from $9.00 to $8.00 and set a “hold” rating on the stock in a research report on Monday, May 11th. Weiss Ratings lowered shares of Senseonics Holdings, Inc. Common Stock from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Wednesday. Finally, Mizuho dropped their price objective on Senseonics Holdings, Inc. Common Stock from $20.00 to $18.00 and set an “outperform” rating on the stock in a research note on Wednesday, July 15th.

Hedge Funds Weigh In On Senseonics Holdings, Inc. Common Stock

Several large investors have recently added to or reduced their stakes in SENS. Ausdal Financial Partners Inc. raised its stake in shares of Senseonics Holdings, Inc. Common Stock by 50.0% in the 3rd quarter. Ausdal Financial Partners Inc. now owns 105,000 shares of the company’s stock valued at $46,000 after buying an additional 35,000 shares in the last quarter. GSK plc bought a new position in shares of Senseonics Holdings, Inc. Common Stock in the fourth quarter valued at approximately $60,000. The Manufacturers Life Insurance Company bought a new position in Senseonics Holdings, Inc. Common Stock in the 2nd quarter valued at $65,000. State of Wyoming bought a new position in shares of Senseonics Holdings, Inc. Common Stock in the second quarter valued at about $67,000. Finally, Kestra Advisory Services LLC bought a new position in shares of Senseonics Holdings, Inc. Common Stock in the first quarter worth about $68,000. Institutional investors and hedge funds own 12.36% of the company’s stock.

Senseonics Holdings, Inc. Common Stock Price Performance

Shares of SENS opened at $7.81 on Wednesday. The company has a debt-to-equity ratio of 0.62, a current ratio of 6.74 and a quick ratio of 6.40. The firm has a market cap of $326.46 million, a PE ratio of -3.50 and a beta of 1.01. The stock has a 50 day simple moving average of $5.95. Senseonics Holdings, Inc. Common Stock has a 12-month low of $4.79 and a 12-month high of $11.58.

Senseonics Holdings, Inc. Common Stock (NASDAQ:SENS) last announced its earnings results on Thursday, August 6th. The company reported ($0.63) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.08). The company had revenue of $14.48 million for the quarter. Senseonics Holdings, Inc. Common Stock had a negative return on equity of 165.80% and a negative net margin of 225.09%. As a group, equities research analysts forecast that Senseonics Holdings, Inc. Common Stock will post -2.29 EPS for the current fiscal year.

About Senseonics Holdings, Inc. Common Stock

Senseonics Holdings, Inc develops and commercializes long-term implantable continuous glucose monitoring (CGM) systems for people with diabetes. The company’s primary product family is the Eversense system, which combines a small subcutaneously implanted sensor, a removable external transmitter, and companion smartphone applications to provide continuous glucose readings and alerts. Senseonics positions its technology as an alternative to wearable patch-style CGMs by offering multi-month sensor longevity and on-body vibration alerts delivered through the transmitter.

Senseonics supports clinical and commercial activities that include research and development, regulatory engagement, manufacturing and distribution, and training for healthcare providers who perform sensor insertion and removal.